Evaluation of Convalescent Plasma Therapy for COVID-19 Patients

Early Phase 1

• Conditions: COVID-19.; COVID-19; U07.1

• Registration Number: IRCT20200503047281N1
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

age between 20 to 60 years old

Exclusion Criteria

People with a history of other immune, genetic or infectious diseases other than corona
Individual suspended but negative for clinical standard covid-19 test

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients discharged from the intensive care unit and hospital. Timepoint: Measurement of all standard clinical signs of the disease before the start of plasma therapy and after the start of each injection of plasma over specific intervals of up to one year (if surviving). Method of measurement: Patient file information.

Secondary Outcome Measures

Name	Time	Method
Patient mortality rate. Timepoint: Recording the mortality rate for one year after starting plasma therapy. Method of measurement: Patient file information.